“With competitive bidding and declining reimbursement rates, demands are being placed on manufacturers to reduce prices, and in order to remain competitive with companies such as ResMed, Fisher & Paykel Healthcare Corporation Limited, and Philips Respironics, we believe moving toward a direct sales model is the right thing to do. DeVilbiss was a good partner for many years, but with the recent changes in the health care environment, InnoMed has to plan for the future and create a solid business model for our customers and investors,” states Ron Richard, CEO of InnoMed Technologies.
InnoMed Technologies will remain dedicated to developing innovative sleep and respiratory products while putting a greater emphasis on their direct relationship with its customers. Bringing the sales efforts in house will broaden the reach of their product mix, and a renewed focus on customer care and educational support for patients and clinicians will facilitate continued breakthroughs in interface technologies.
“We have been in close contact with the senior staff at DeVilbiss to ensure a smooth transition occurs and patients are not without the products they depend on for their treatment of sleep disorders,” said Richard. “The transition begins August 12th, and over the next few weeks we will be contacting providers to insure they have the right information to place orders directly with InnoMed Technologies.”